Abstract: Methods of treating Tau-associated diseases, preferably tauopathies, are described using epothilone D that exhibit good brain penetration, long half-life, and high selective retention in brain, and provides effective therapies in treating tauopathies including Alzheimer's disease.

Abstract: Methods of treating Tau-associated diseases, preferably tauopathies, are described using epothilone D that exhibit good brain penetration, long half-life, and high selective retention in brain, and provides effective therapies in treating tauopathies including Alzheimer's disease.

Abstract: Methods of treating Tau-associated diseases, preferably tauopathies, are described using epothilone D that exhibit good brain penetration, long half-life, and high selective retention in brain, and provides effective therapies in treating tauopathies including Alzheimer's disease.

Abstract: Methods of treating Tau-associated diseases, preferably tauopathies, are described using epothilone D that exhibit good brain penetration, long half-life, and high selective retention in brain, and provides effective therapies in treating tauopathies including Alzheimer's disease.

Abstract: In vitro cell-based methods for identifying compounds that inhibit Notch cleavage and methods for identifying ?-secretase inhibitors that exhibit reduced induction of goblet cell metaplasia are provided. Also provided are methods of identifying compounds that inhibit cleavage of ?-secretase substrates other than Notch and homogeneous compositions or cultures of Notch-expressing cells that undergo mucin-2 or mucin-5AC induction in response to a compound known to inhibit Notch cleavage and methods of their generation.

Abstract: This invention is directed to antineoplastic agents conjugated to enzyme-cleavable peptides comprising the amino acid recognition sequence of a membrane-bound and/or cell-secreted peptidase, and to the use of such conjugated compounds as chemotherapeutic agents in the targeted treatment of cancers.

Abstract: This invention is directed to antineoplastic agents conjugated to enzyme-cleavable peptides comprising the amino acid recognition sequence of a membrane-bound and/or cell-secreted peptidase, and to the use of such conjugated compounds as chemotherapeutic agents in the targeted treatment of cancers.

Abstract: The classical Reimer-Tiemann reaction for the synthesis of phenolic aldehydes has been modified from an aqueous to a non-aqueous system to provide an improved route for the formation of salicylaldehydes and, preferably, 3-substituted salicylaldehydes, e.g. 3-fluorosalicylaldehyde. Heretofore, compounds such as 3-substituted salicylaldehydes have proven to be extremely difficult to prepare in other than small laboratory quantities from the corresponding ortho-substituted phenol, since, in the final salicylaldehyde, each position ortho to the hydroxyl group contains substitution. In particular, with respect to 3-fluorosalicylaldehyde, one of the positions is occupied by the strongly electronegative fluorine atom so that the principal reaction product in the aqueous Reimer-Tiemann reaction has always been the para-isomer (3-fluoro-4-hydroxy-benzaldehyde), only negligible quantities of the desired ortho-isomer being obtained.